Saama is a company that focuses on the development of life science solutions to expedite the delivery of therapies to patients. With a strong emphasis on innovative AI technologies, the company aims to bring breakthrough intelligence into clinical and commercial operations. Notably, the Saama platform played a pivotal role in the clinical trial that resulted in the development of the world’s first COVID-19 vaccine. Established in 1997, Saama is headquartered in Campbell, CA and has a global presence with employees across the world. The company is dedicated to assisting customers in saving and enhancing lives. Operating within the Analytics and Pharmaceutical industries, Saama received a significant $40.00M Venture Round investment on 25th March 2019, with Perceptive Advisors being the contributing investors. For more information, visit saama.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $40.00M | 1 |
|
25 Mar 2019 |
| Series A | $35.75M | 1 |
|
02 Jun 2015 |
No recent news or press coverage available for Saama.
We care about your data, and we'd love to use cookies make your experience better.
